Anatara Lifesciences (ASX:ANR) Shareholder Yield % : -34.21% (As of Dec. 2025)


What is Anatara Lifesciences Shareholder Yield %?

Anatara Lifesciences ASX:ANR Shareholder Yield % is -34.21% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 1,299 Biotechnology companies, Anatara Lifesciences ranks worse than 86.53% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Anatara Lifesciences's Shareholder Yield % was -34.21%.


Anatara Lifesciences  (ASX:ANR) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Anatara Lifesciences Shareholder Yield % Related Terms


Anatara Lifesciences Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Anatara Lifesciences's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anatara Lifesciences Shareholder Yield % Chart

Anatara Lifesciences Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.19 0.36 -44.43 -22.77 -92.98

Anatara Lifesciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.44 -22.77 -18.71 -92.98 -24.62

ASX:ANR vs VRTX, REGN, ALNY: Shareholder Yield % Comparison

For the Biotechnology subindustry, Anatara Lifesciences's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anatara Lifesciences Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anatara Lifesciences's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Anatara Lifesciences's Shareholder Yield % falls into.



Anatara Lifesciences Shareholder Yield % Calculation

Anatara Lifesciences's Shareholder Yield % for the quarter that ended in Dec. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-24.62 %+0 %
=-24.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -34.21% mean?
Anatara Lifesciences (ASX:ANR) has a Shareholder Yield % of -34.21% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Anatara Lifesciences and its competitors. According to the industry distribution chart, Anatara Lifesciences ranks #1124 out of 1299 companies in the Biotechnology industry, placing it in the top 86.5%.
Is Anatara Lifesciences' Shareholder Yield % too high?
Anatara Lifesciences' current Shareholder Yield % is -34.21%. Based on the distribution chart, Anatara Lifesciences ranks #1124 out of 1299 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Anatara Lifesciences' Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anatara Lifesciences ranks #1124 out of 1299 companies for Shareholder Yield %. This places Anatara Lifesciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Anatara Lifesciences and its competitors. Anatara Lifesciences's current Shareholder Yield % is -34.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anatara Lifesciences stock overvalued right now?
Anatara Lifesciences (ASX:ANR) has a current Shareholder Yield % of -34.21%. The current Shareholder Yield % is -34.21%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Anatara Lifesciences (ASX:ANR), the current Shareholder Yield % is -34.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anatara Lifesciences Business Description

Address c/- Perks, 81 Flinders Street, Level 8, Adelaide, SA, AUS, 5000
Anatara Lifesciences Ltd develops and commercializes evidence-based products addressing unmet needs in gastrointestinal health. The company focuses on building a pipeline of human health products, particularly targeting complex gastrointestinal conditions. It operates through a single reportable segment encompassing the research and development of oral solutions for gastrointestinal diseases and the commercialization of Detach, a diarrhea treatment for piglets.